Pulmonary Veno-Occlusive Disease (Veno Occlusive Disease, Pulmonary)

Pathological process resulting in the fibrous obstruction of the small- and medium-sized PULMONARY VEINS and PULMONARY HYPERTENSION. Veno-occlusion can arise from fibrous proliferation of the VASCULAR INTIMA and VASCULAR MEDIA; THROMBOSIS; or a combination of both.
Also Known As:
Veno Occlusive Disease, Pulmonary; Pulmonary Veno Occlusive Disease; Pulmonary Venoocclusive Disease; Diseases, Pulmonary Veno-Occlusive; Pulmonary Veno-Occlusive Diseases; Pulmonary Venoocclusive Diseases; Veno-Occlusive Diseases, Pulmonary; Venoocclusive Disease, Pulmonary; Venoocclusive Diseases, Pulmonary; Veno-Occlusive Disease, Pulmonary
Networked: 131 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Heart Diseases (Heart Disease)
2. Portal Hypertension
3. Connective Tissue Diseases (Connective Tissue Disease)
4. Pulmonary Hypertension (Ayerza Syndrome)
5. Vascular Diseases (Vascular Disease)


1. Humbert, Marc: 11 articles (12/2015 - 03/2002)
2. Montani, David: 8 articles (12/2015 - 08/2009)
3. Sitbon, Olivier: 7 articles (09/2015 - 03/2002)
4. Simonneau, Gérald: 6 articles (12/2015 - 07/2004)
5. Girerd, Barbara: 5 articles (12/2015 - 04/2011)
6. Jaïs, Xavier: 5 articles (12/2015 - 01/2010)
7. Simonneau, G: 5 articles (12/2009 - 11/2003)
8. Savale, Laurent: 4 articles (12/2015 - 07/2010)
9. Dorfmüller, Peter: 4 articles (12/2015 - 07/2012)
10. Fadel, Elie: 4 articles (12/2015 - 05/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Pulmonary Veno-Occlusive Disease:
1. Epoprostenol (Prostacyclin)FDA LinkGeneric
2. sorafenib (BAY 43-9006)FDA Link
3. Idiopathic pulmonary hypertensionIBA
4. Nitric Oxide (Nitrogen Monoxide)FDA Link
5. Mitomycin (Mitomycin-C)FDA LinkGeneric
6. CollagenIBA
10/01/2012 - "We assessed HbA1c levels in 115 patients newly diagnosed with PAH (79 females and 36 males; mean age 49.2 years; idiopathic n = 67, collagen vascular disease n = 16, congenital heart defect n = 19, pulmonary veno-occlusive disease n = 8, portopulmonary n = 5). "
01/01/2007 - "This classification abandons terms "primary" and "secondary" PH. Primary PH which is now recommended to be called "idiopathic pulmonary arterial hypertension" is grouped in one category with familial cases of PH, PH associated with administration of anorexigens, collagen vascular disease, congenital systemic to pulmonary shunts, portal hypertension and hyperthyroidism, as well as with pulmonary veno-occlusive disease and and pulmonary capillary hemangiomatosis, taking into consideration similarity of histopathological changes of vascular tree, pathophysiology and therapeutic approaches in these forms of PH."
01/01/2006 - "Pulmonary arterial hypertension can be classified into five categories according to Venice classification: (1) Idiopathic PAH; (2) Familial PAH; (3) PAH associated with collagen vascular disease, congenital systemic-to-pulmonary shunts, portal hypertension, HIV infection, drugs and toxins or other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy); (4) PAH associated with significant venous or capillary involvement, which includes pulmonary veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH); (5) Persistent pulmonary hypertension of the newborn. "
7. Bleomycin (Blenoxane)FDA LinkGeneric
8. Mediastinal FibrosisIBA
9. sildenafil (Viagra)FDA Link
10. gemcitabineFDA Link

Therapies and Procedures

1. Lung Transplantation
2. Drug Therapy (Chemotherapy)
3. Bone Marrow Transplantation (Transplantation, Bone Marrow)
4. Transplantation (Transplant Recipients)
5. Peripheral Blood Stem Cell Transplantation (Peripheral Stem Cell Transplantation)